Tag
A quality improvement initiative integrating oral anticoagulants reduced venous thromboembolism incidence in ovarian cancer patients undergoing first-line chemotherapy without increasing bleeding risks.
This review synthesizes evidence linking NOAC use to slower cognitive decline and improved clinical outcomes in patients with atrial fibrillation and Alzheimer’s disease, highlighting advantages over warfarin and non-use.
This study evaluates the incidence, severity, and predictors of extracranial bleeding in atrial fibrillation patients on oral anticoagulants, highlighting its substantial burden beyond major bleeds and informing bleeding risk management.
Recent decades saw increased anticoagulant use and reduced stroke risk in elderly AF patients, especially with DOACs, but bleeding risks rise notably in very elderly patients, highlighting tailored management needs.
A nationwide cohort study demonstrates that NSAID use in patients with atrial fibrillation on oral anticoagulants nearly doubles the risk of hospital-diagnosed bleeding, with significant risks observed across all anticoagulant types and mul
Danish registry data (1999–2022) show large reductions in stroke across age groups with widespread oral anticoagulant (OAC) uptake, but only modest stroke gains and rising intracerebral hemorrhage in patients ≥85 years, highlighting the nee
Continued oral anticoagulant therapy after ≥90 days for unprovoked VTE significantly lowers recurrence and mortality despite increased bleeding risk, offering a net clinical benefit consistent across anticoagulant types and treatment durati
The ALONE-AF trial reveals that discontinuation of oral anticoagulants post-successful atrial fibrillation ablation may reduce stroke, systemic embolism, and major bleeding compared to continued therapy, informing anticoagulation strategies
